Eczema (Atopic Dermatitis) [2026]: Causes, Triggers, and Prescription Treatment Options

Last updated: September 19, 2026 Reviewed by PrescribedGlow Editorial Team, Editorial

Disclosure: This page contains affiliate links. If you purchase through our links, we may earn a commission at no extra cost to you. Our editorial opinions are our own.

Eczema (atopic dermatitis) is a chronic inflammatory skin disorder caused by epidermal barrier dysfunction, filaggrin gene mutations, and immune hyperreactivity. It manifests as dry, severely itchy, and erythematous skin plaques. While incurable, modern prescription treatments—including topical corticosteroids, non-steroidal calcineurin inhibitors, topical JAK inhibitors, and targeted biologics—effectively suppress inflammation and manage debilitating flare-ups.

What is the difference between eczema and atopic dermatitis?

The primary difference is scope: eczema is an umbrella medical term describing multiple inflammatory skin conditions, whereas atopic dermatitis is the most prevalent, chronic form of eczema. Atopic dermatitis specifically involves an inherited deficiency in skin barrier proteins, elevated immunoglobulin E (IgE), and a strong genetic predisposition toward asthma and allergic rhinitis.

The following table outlines the clinical distinctions between atopic dermatitis and related facial and bodily rashes:

Clinical Feature Atopic Dermatitis Seborrheic Dermatitis Rosacea Allergic Contact Dermatitis
Lesion Appearance Dry, rough, lichenified excoriated plaques Greasy, oily, yellowish scales Erythematous papules, flushing, telangiectasia Vesicles, oozing blisters, sharp borders
Typical Distribution Flexural creases (elbows, knees), neck, hands Scalp, eyebrows, nasolabial folds, ears Central face (cheeks, nose, forehead) Site of allergen contact (eyelids, hands)
Primary Mechanism FLG gene mutation & Th2 immune cascade Malassezia yeast & sebaceous dysbiosis Neurovascular reactivity & Demodex mites Type IV delayed hypersensitivity (T-cell)
Itch Severity Intense, unyielding, sleep-disrupting pruritus Mild to moderate itch or stinging Stinging, burning, rarely true itch Severe, localized burning itch
Barrier Response Benefits from dense lipid barrier balms Worsens with heavy oils; needs antifungals Requires lightweight, soothing creams Requires allergen removal and barrier repair

Atopic dermatitis represents a substantial healthcare burden in adults. In a national, population-based investigation published in Annals of Allergy, Asthma & Immunology (Silverberg et al., 2019; PMID: 30389491), researchers analyzed 1,278 adult atopic dermatitis patients in the United States. The study established that adult eczema affects approximately 7.3% of the U.S. population (roughly 16.5 million adults). Moreover, 40% of adult patients suffered from moderate-to-severe disease, with severe pruritus causing sleep disruption in more than 60% of cases.

What causes eczema flare-ups?

Eczema flare-ups occur when environmental irritants or internal physiological stressors penetrate a compromised stratum corneum. Major triggers include dry winter weather, hot water, synthetic fragrances, harsh sulfate detergents, emotional stress, and Staphylococcus aureus bacterial colonization. These factors initiate an exaggerated inflammatory cascade, causing rapid barrier breakdown and intense pruritus.

In healthy skin, extracellular lipids (ceramides, cholesterol, and free fatty acids) seal moisture inside the stratum corneum. In atopic skin, loss-of-function mutations in the filaggrin (FLG) gene diminish natural moisturizing factors, accelerating transepidermal water loss (TEWL) and micro-fissuring. Common flare catalysts include:

  • Low Humidity & Dry Climates: Cold, low-humidity winter air saps epidermal moisture, while prolonged hot showers strip protective surface lipids.
  • Irritating Chemicals: Fragranced lotions, fabric softeners, and sulfate-based cleansers create micro-abrasions that activate cutaneous nerve fibers.
  • Microbial Dysbiosis: Up to 90% of eczema lesions exhibit overgrowth of Staphylococcus aureus, whose delta-toxins directly trigger mast cell degranulation.
  • Emotional Stress: Elevated cortisol and substance P induce neurogenic inflammation, intensifying the itch-scratch cycle.

Chronic scratching thickens the epidermis into leathery plaques (lichenification), which can sometimes be confused clinically with plaque psoriasis. In skin of color, resolved plaques frequently leave behind stubborn post-inflammatory hyperpigmentation. In follicular regions, impaired cellular shedding often co-occurs with rough bumps known as keratosis pilaris.

What is the best prescription treatment for eczema?

The most effective prescription treatment depends on flare severity, affected body surface area, and skin sensitivity. While topical corticosteroids rapidly quell acute flare-ups, steroid-sparing non-steroidal topicals—including calcineurin inhibitors (tacrolimus, pimecrolimus), PDE4 inhibitors (roflumilast), and JAK inhibitors (ruxolitinib)—deliver robust disease clearance without the risks of skin thinning or rebound flares.

Topical Corticosteroids & Calcineurin Inhibitors

Topical corticosteroids (TCS) remain common agents for acute flare relief. They suppress inflammatory cytokine gene expression. However, prolonged use on thin facial or intertriginous skin risks dermal atrophy, telangiectasias, and steroid rebound resembling perioral dermatitis.

To avoid steroid side effects, dermatologists utilize non-steroidal topical calcineurin inhibitors (TCIs)—including tacrolimus 0.03%/0.1% ointment and pimecrolimus 1% cream. TCIs selectively inhibit T-cell activation without impairing collagen synthesis, making them safe for long-term use on the face, eyelids, and neck.

Next-Generation Non-Steroidal Topicals

Recent pharmaceutical advances have produced targeted non-steroidal topicals with rapid anti-itch efficacy:

  • Topical JAK Inhibitor (Ruxolitinib): Ruxolitinib 1.5% cream (Opzelura) inhibits JAK1 and JAK2 enzymes, intercepting cytokine signaling for IL-4, IL-13, and IL-31. In two Phase 3 randomized trials published in the Journal of the American Academy of Dermatology (Papp et al., 2021; PMID: 33957195) involving 1,249 patients (TRuE-AD1 and TRuE-AD2), 53.8% and 51.3% of patients applying 1.5% ruxolitinib cream achieved IGA treatment success (clear or almost clear skin) at Week 8, compared to 15.1% and 7.6% on vehicle cream, with notable itch reduction within 12 hours.

  • Targeted PDE4 Inhibitor (Roflumilast): Roflumilast 0.15% cream (Zoryve) inhibits phosphodiesterase-4, preventing cyclic AMP breakdown to calm inflammatory mediator release. In two Phase 3 randomized trials published in JAMA Dermatology (Simpson et al., 2024; PMID: 39292443) encompassing 1,337 patients (INTEGUMENT-1 and INTEGUMENT-2), once-daily roflumilast cream 0.15% achieved Validated Investigator Global Assessment (vIGA-AD) success at Week 4 in 32.0% and 28.9% of patients, versus 15.2% and 12.0% for vehicle ($p < 0.001$).

Systemic Biologics

For moderate-to-severe eczema covering extensive body surface area that resists topical regimens, injectable biologics like dupilumab (Dupixent) and tralokinumab (Adbry) selectively neutralize IL-4 and IL-13 cytokines. These targeted therapies restore the immune balance without broad systemic immunosuppression.

Can you get prescription eczema treatment online?

Yes, accessing prescription eczema treatments online is simple through modern teledermatology services like Honeydew Care, Ro Derm, and Dermatica. Licensed healthcare providers evaluate your medical history and skin photographs through secure digital consultations, prescribing non-steroidal topicals, compounded barrier creams, or prescription rinses shipped straight to your door.

Virtual dermatology clinics accommodate different clinical needs:

  • Specialized Medical Dermatology (Honeydew Care): As detailed in our Honeydew vs Curology comparison, Honeydew Care functions as a full-service virtual clinic. Licensed clinicians diagnose chronic medical conditions like eczema and manage insurance coverage for prescription topicals.
  • Custom Formulations (Dermatica & Ro Derm): Platforms like Dermatica and Ro Derm evaluate facial and body rashes asynchronously, prescribing customized anti-inflammatory and barrier creams delivered monthly.
  • Insured Generic Medications (Nurx): Nurx offers online consultations for skin rashes, sending FDA-approved generic topical corticosteroids and calcineurin inhibitors through commercial insurance.

To learn how photograph evaluations and digital prescribing operate, consult our guide on how online dermatology works. If balancing sensitive skin care during pregnancy, review our overview of pregnancy-safe skincare.

Note: If a rash exhibits oozing yellow crusts, rapid swelling, or covers more than 30% of your body, an in-person dermatology visit is required for bacterial culturing and specialized therapy.

Frequently asked questions

What is the difference between eczema and atopic dermatitis? Eczema is a broad clinical term encompassing several inflammatory skin conditions, including contact dermatitis, dyshidrotic eczema, and seborrheic dermatitis. Atopic dermatitis is the most common, chronic, and severe type of eczema, specifically driven by a genetic skin barrier defect and systemic immune dysregulation that frequently co-occurs with allergies and asthma.

What causes eczema flare-ups? Eczema flare-ups are triggered when environmental or internal stressors breach a weakened epidermal barrier. Common precipitants include low humidity, dry winter air, harsh soaps or detergents, synthetic fragrances, fabric friction, emotional stress, and colonization by Staphylococcus aureus bacteria, all of which ignite localized cutaneous cytokine release and severe itching.

What is the best prescription treatment for eczema? The optimal prescription treatment depends on disease severity and anatomical location. For acute flares, short courses of topical corticosteroids calm inflammation. For maintenance and sensitive areas like the face, non-steroidal options—such as calcineurin inhibitors (tacrolimus), PDE4 inhibitors (roflumilast), and topical JAK inhibitors (ruxolitinib)—provide sustained symptom relief without dermal atrophy.

Can eczema be cured permanently? No, eczema cannot be permanently cured because it stems from underlying genetic alterations in skin barrier proteins and systemic immune signaling. However, patients can achieve long-term remission and symptom-free intervals through consistent ceramide moisturizing, identifying personal environmental triggers, and using targeted non-steroidal or biologic prescription therapies during exacerbations.

Can you get prescription eczema treatment online? Yes, telehealth dermatology platforms like Honeydew Care, Ro Derm, and Dermatica evaluate eczema asynchronously or via video. Board-certified dermatologists and licensed clinicians review photographs of your rash, assess flare severity, and electronically prescribe targeted non-steroidal creams, steroid-sparing topicals, or maintenance therapies delivered directly to your home.

Is eczema contagious? No, eczema is completely non-contagious. It cannot spread from person to person through physical touch, shared clothing, or skin-to-skin contact. The redness, scaling, and flaking are caused by genetic skin barrier variations and internal immune overactivity rather than an infectious bacterial, viral, or fungal pathogen.

Bottom line

Atopic dermatitis is a chronic, relapsing condition rooted in epidermal barrier impairment and immune hyperactivity. While over-the-counter moisturizers rich in ceramides provide foundational hydration, managing inflammatory flare-ups requires targeted medical care. With modern non-steroidal topicals like calcineurin inhibitors, roflumilast, and ruxolitinib, patients can achieve rapid itch relief and clear skin without the risks of steroid-induced skin thinning.

Explore our Honeydew vs Curology comparison · Read our Dermatica review · Read our Ro Derm review · Read our Nurx review

Sources

  • Silverberg JI, Gelfand JM, Margolis DJ, et al. Patient burden and quality of life in atopic dermatitis in US adults: A population-based cross-sectional study. Annals of Allergy, Asthma & Immunology. 2019;121(3):340-347. PMID: 30389491. https://pubmed.ncbi.nlm.nih.gov/30389491/
  • Papp K, Szepietowski JC, Kircik L, et al. Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: Results from 2 phase 3, randomized, double-blind studies. Journal of the American Academy of Dermatology. 2021;85(4):863-872. PMID: 33957195. https://pubmed.ncbi.nlm.nih.gov/33957195/
  • Simpson EL, Gooderham M, Wollenberg A, et al. Roflumilast Cream, 0.15%, for Atopic Dermatitis in Adults and Children: INTEGUMENT-1 and INTEGUMENT-2 Randomized Clinical Trials. JAMA Dermatology. 2024;160(11):1147-1156. PMID: 39292443. https://pubmed.ncbi.nlm.nih.gov/39292443/